COLLEGIUM PHARMACEUTICAL, INC COLL revenue by segment, product and geography
In its fiscal year ending 2025-12-31, COLLEGIUM PHARMACEUTICAL, INC reported revenue across 1 business segments; the largest, Single Reportable Segment, was $781M, 100.0% of the filed sum (+23.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Single Reportable Segment$781M100.0%+23.6% yoy
Members sum to the consolidated $781M for this period.
- Belbuca$222M28.4%+4.9% yoy
- Xtampza ER$199M25.5%+4.2% yoy
- Jornay Pm$149M19.1%+299.7% yoy
- Nucynta IR$115M14.8%+14.5% yoy
- Nucynta ER$81M10.4%+6.9% yoy
- Symproic And Other$14.5M1.9%-4.3% yoy
Members sum to the consolidated $781M for this period.
- Single Reportable Segment$194M100.0%+8.9% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.